Business Context and Reporting Period
Company: ORIC Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2024
Reporting Period: Fiscal quarter ended June 30, 2024
Context: The filing serves to announce the company's financial results for the second quarter of 2024 via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained within the referenced press release (Exhibit 99.1), which is not included in the input text. Therefore, the filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The document solely references the issuance of the Q2 2024 results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release by reference but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are described in the provided text.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2024 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if the company provided updated full-year 2024 financial guidance in the press release.